| Aug 8 |
Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant
|
| Aug 8 |
Sanofi’s Sarclisa wins in transplant-eligible multiple myeloma trial
|
| Aug 8 |
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
|
| Aug 8 |
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
|
| Aug 3 |
Where Will Novavax Be in 5 Years?
|
| Aug 2 |
Vir Bio trims staff and pipeline to focus on Sanofi-licensed programmes
|
| Aug 2 |
Sanofi invests $1.4bn in insulin production in Germany
|
| Aug 2 |
Q2 2024 Regeneron Pharmaceuticals Inc Earnings Call
|
| Aug 1 |
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
|
| Aug 1 |
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
|
